Sachi Bio has been selected to provide potential scientific and commercialization evidence for use of accelerated aging and neurodegeneration in LEO for high-throughput, rapid, and low-cost drug-discovery. The SBIR Phase III award was granted to Sachi Bio for their proposed “Rapid, Low-Cost Drug-Discovery in Space” project.
It aligns with InSPA’s goals of developing applications that benefit humanity. The space-based therapeutic screening can potentially accelerate drug-development for diseases such as neurodegeneration, cardiovascular, and cancer, by leveraging the accelerated disease progression due to microgravity and radiation. Commercialization objectives also include translating the molecules developed here as a combination therapy for cancer radiotherapy patients, to improve outcomes.